EFEMP1 and glioblastoma: Although we had a limited number of samples, a clear trend could be observed towards an increased expression of EFEMP1 in glioblastoma samples at the time of progression (Fig. 6C), suggesting that EFEMP1 could be used as a marker for tumor progression after TMZ treatment.